NCT00438802 - Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

August 24, 2010

Study Completion Date

July 25, 2019

Conditions

Lymphoma

Interventions

DRUG

Alefacept

Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8

Trial Locations (3)

Mayo Clinic Cancer Center, Rochester

City of Hope Comprehensive Cancer Center, Duarte

Holden Comprehensive Cancer Center at University of Iowa, Iowa City